Gut microbes in cardiovascular diseases and their potential therapeutic applications

Abstract

Microbial ecosystem comprises a complex community in which bacteria interact with each other. The potential roles of the intestinal microbiome play in human health have gained considerable attention. The imbalance of gut microbial community has been looked to multiple chronic diseases. Cardiovascular diseases (CVDs) are leading causes of morbidity worldwide and are influenced by genetic and environmental factors. Recent advances have provided scientific evidence that CVD may also be attributed to gut microbiome. In this review, we highlight the complex interplay between microbes, their metabolites, and the potential influence on the generation and development of CVDs. The therapeutic potential of using intestinal microbiomes to treat CVD is also discussed. It is quite possible that gut microbes may be used for clinical treatments of CVD in the near future.

Key words： gut microbiota; cardiovascular diseases; action mechanism; therapeutic applications

References

1 Adnan S, Nelson JW, Ajami NJ, Venna VR, Petrosino JF, Bryan RM Jr, Durgan DJ (2017) Alterations in the gut microbiota can elicit hypertension in rats. Physiol Genomics 49:96–104

2 Aguilar EC, Leonel AJ, Teixeira LG, Silva AR, Silva JF, Pelaez JM, Capettini LS, Lemos VS, Santos RA, Alvarez-Leite JI (2014) Butyrate impairs atherogenesis by reducing plaque inflammation and vulnerability and decreasing NFkappaB activation. Nutr Metab Cardiovasc Dis 24:606–613

3 Ahmad AF, Dwivedi G, O’Gara F, Caparros-Martin J, Ward NC (2019) The gut microbiome and cardiovascular disease: current knowledge and clinical potential. Am J Physiol Heart Circ Physiol 317:H923–H938

4 Appel LJ, Moore TJ, Obarzanek E, Vollmer WM, Svetkey LP, Sacks FM, Bray GA, Vogt TM, Cutler JA, Windhauser MM (1997) A clinical trial of the effects of dietary patterns on blood pressure. DASH Collaborative Research Group. N Engl J Med 336:1117–1124

5 Azad MAK, Sarker M, Li T, Yin J (2018) Probiotic species in the modulation of gut microbiota: an overview. Biomed Res Int 2018:9478630

6 Bartolomaeus H, Balogh A, Yakoub M, Homann S, Marko L, Hoges S, Tsvetkov D, Krannich A, Wundersitz S, Avery EG (2019) Short-chain fatty acid propionate protects from hypertensive cardiovascular damage. Circulation 139:1407–1421

7 Battson ML, Lee DM, Jarrell DK, Hou S, Ecton KE, Weir TL, Gentile CL (2018a) Suppression of gut dysbiosis reverses Western dietinduced vascular dysfunction. Am J Physiol Endocrinol Metab 314:E468–E477

8 Battson ML, Lee DM, Weir TL, Gentile CL (2018b) The gut microbiota as a novel regulator of cardiovascular function and disease. J Nutr Biochem 56:1–15

9 Blacher E, Levy M, Tatirovsky E, Elinav E (2017) Microbiomemodulated metabolites at the interface of host immunity. J Immunol 198:572–580

10 Brunt VE, Gioscia-Ryan RA, Casso AG, VanDongen NS, Ziemba BP, Sapinsley ZJ, Richey JJ, Zigler MC, Neilson AP, Davy KP (2020) Trimethylamine-N-oxide promotes age-related vascular oxidative stress and endothelial dysfunction in mice and healthy humans. Hypertension 76:101–112

11 Cason CA, Dolan KT, Sharma G, Tao M, Kulkarni R, Helenowski IB, Doane BM, Avram MJ, McDermott MM, Chang EB (2018) Plasma microbiome-modulated indoleand phenyl-derived metabolites associate with advanced atherosclerosis and postoperative outcomes. J Vasc Surg 68(1552–1562):e1557

12 Castillo DJ, Rifkin RF, Cowan DA, Potgieter M (2019) The healthy human blood microbiome: fact or fiction? Front Cell Infect Microbiol 9:148

13 Chan YK, Brar MS, Kirjavainen PV, Chen Y, Peng J, Li D, Leung FC, El-Nezami H (2016a) High fat diet induced atherosclerosis is accompanied with low colonic bacterial diversity and altered abundances that correlates with plaque size, plasma A-FABP and cholesterol: a pilot study of high fat diet and its intervention with Lactobacillus rhamnosus GG (LGG) or telmisartan in ApoE (-/-) mice. BMC Microbiol 16:264

14 Chan YK, El-Nezami H, Chen Y, Kinnunen K, Kirjavainen PV (2016b) Probiotic mixture VSL#3 reduce high fat diet induced vascular inflammation and atherosclerosis in ApoE(-/-) mice. AMB Express 6:61

15 Chen S, Henderson A, Petriello MC, Romano KA, Gearing M, Miao J, Schell M, Sandoval-Espinola WJ, Tao J, Sha B (2019) Trimethylamine N-oxide binds and activates PERK to promote metabolic dysfunction. Cell Metab 30(1141–1151):e1145

16 Cheng YJ, Nie XY, Chen XM, Lin XX, Tang K, Zeng WT, Mei WY, Liu LJ, Long M, Yao FJ (2015) The role of macrolide antibiotics in increasing cardiovascular risk. J Am Coll Cardiol 66:2173–2184

17 Cheung F (2011) TCM: made in China. Nature 480:S82–83

18 Clemente JC, Ursell LK, Parfrey LW, Knight R (2012) The impact of the gut microbiota on human health: an integrative view. Cell 148:1258–1270

19 Cui X, Ye L, Li J, Jin L, Wang W, Li S, Bao M, Wu S, Li L, Geng B (2018) Metagenomic and metabolomic analyses unveil dysbiosis of gut microbiota in chronic heart failure patients. Sci Rep 8:635

20 David LA, Maurice CF, Carmody RN, Gootenberg DB, Button JE, Wolfe BE, Ling AV, Devlin AS, Varma Y, Fischbach MA (2014) Diet rapidly and reproducibly alters the human gut microbiome. Nature 505:559–563

21 Davignon J, Ganz P (2004) Role of endothelial dysfunction in atherosclerosis. Circulation 109:III27–III32

22 De Filippis F, Pellegrini N, Vannini L, Jeffery IB, La Storia A, Laghi L, Serrazanetti DI, Di Cagno R, Ferrocino I, Lazzi C (2016) High-level adherence to a Mediterranean diet beneficially impacts the gut microbiota and associated metabolome. Gut 65:1812–1821

23 Desai MS, Seekatz AM, Koropatkin NM, Kamada N, Hickey CA, Wolter M, Pudlo NA, Kitamoto S, Terrapon N, Muller A (2016) A dietary fiber-deprived gut microbiota degrades the colonic mucus barrier and enhances pathogen susceptibility. Cell 167(1339–1353):e1321

24 Dinakaran V, John L, Rathinavel A, Gunasekaran P, Rajendhran J (2012) Prevalence of bacteria in the circulation of cardiovascular disease patients, Madurai, India. Heart Lung Circ 21:281–283

25 Dinakaran V, Rathinavel A, Pushpanathan M, Sivakumar R, Gunasekaran P, Rajendhran J (2014) Elevated levels of circulating DNA in cardiovascular disease patients: metagenomic profiling of microbiome in the circulation. PLoS ONE 9:e105221

26 Donohoe DR, Garge N, Zhang X, Sun W, O’Connell TM, Bunger MK, Bultman SJ (2011) The microbiome and butyrate regulate energy metabolism and autophagy in the mammalian colon. Cell Metab 13:517–526

27 Duncan SH, Belenguer A, Holtrop G, Johnstone AM, Flint HJ, Lobley GE (2007) Reduced dietary intake of carbohydrates by obese subjects results in decreased concentrations of butyrate and butyrate-producing bacteria in feces. Appl Environ Microbiol 73:1073–1078

28 Durgan DJ, Ganesh BP, Cope JL, Ajami NJ, Phillips SC, Petrosino JF, Hollister EB, Bryan RM Jr (2016) Role of the gut microbiome in obstructive sleep apnea-induced hypertension. Hypertension 67:469–474

29 Fak F, Backhed F (2012) Lactobacillus reuteri prevents diet-induced obesity, but not atherosclerosis, in a strain dependent fashion in Apoe-/mice. PLoS ONE 7:e46837

30 Franzosa EA, Hsu T, Sirota-Madi A, Shafquat A, Abu-Ali G, Morgan XC, Huttenhower C (2015) Sequencing and beyond: integrating molecular ‘omics’ for microbial community profiling. Nat Rev Microbiol 13:360–372

31 Fukami K, Yamagishi S, Sakai K, Kaida Y, Yokoro M, Ueda S, Wada Y, Takeuchi M, Shimizu M, Yamazaki H (2015) Oral L-carnitine supplementation increases trimethylamine-N-oxide but reduces markers of vascular injury in hemodialysis patients. J Cardiovasc Pharmacol 65:289–295

32 Gan XT, Ettinger G, Huang CX, Burton JP, Haist JV, Rajapurohitam V, Sidaway JE, Martin G, Gloor GB, Swann JR (2014) Probiotic administration attenuates myocardial hypertrophy and heart failure after myocardial infarction in the rat. Circ Heart Fail 7:491–499

33 Gomez-Arango LF, Barrett HL, McIntyre HD, Callaway LK, Morrison M, Dekker Nitert M, Group ST (2016) Increased systolic and diastolic blood pressure is associated with altered gut microbiota composition and butyrate production in early pregnancy. Hypertension 68:974–981

34 Gomez-Guzman M, Toral M, Romero M, Jimenez R, Galindo P, Sanchez M, Zarzuelo MJ, Olivares M, Galvez J, Duarte J (2015) Antihypertensive effects of probiotics Lactobacillus strains in spontaneously hypertensive rats. Mol Nutr Food Res 59:2326–2336

35 Gozd-Barszczewska A, Koziol-Montewka M, Barszczewski P, Mlodzinska A, Huminska K (2017) Gut microbiome as a biomarker of cardiometabolic disorders. Ann Agric Environ Med 24:416–422

36 Halkjaer SI, Christensen AH, Lo BZS, Browne PD, Gunther S, Hansen LH, Petersen AM (2018) Faecal microbiota transplantation alters gut microbiota in patients with irritable bowel syndrome: results from a randomised, double-blind placebocontrolled study. Gut 67:2107–2115

37 He K, Hu Y, Ma H, Zou Z, Xiao Y, Yang Y, Feng M, Li X, Ye X (2016) Rhizoma Coptidis alkaloids alleviate hyperlipidemia in B6 mice by modulating gut microbiota and bile acid pathways. Biochim Biophys Acta 1862:1696–1709

38 Honour JW, Borriello SP, Ganten U, Honour P (1985) Antibiotics attenuate experimental hypertension in rats. J Endocrinol 105:347–350

39 Huang Y, Wang J, Quan G, Wang X, Yang L, Zhong L (2014) Lactobacillus acidophilus ATCC 4356 prevents atherosclerosis via inhibition of intestinal cholesterol absorption in apolipoprotein E-knockout mice. Appl Environ Microbiol 80:7496–7504

40 Isabella VM, Ha BN, Castillo MJ, Lubkowicz DJ, Rowe SE, Millet YA, Anderson CL, Li N, Fisher AB, West KA (2018) Development of a synthetic live bacterial therapeutic for the human metabolic disease phenylketonuria. Nat Biotechnol 36:857–864

41 Jie Z, Xia H, Zhong SL, Feng Q, Li S, Liang S, Zhong H, Liu Z, Gao Y, Zhao H (2017) The gut microbiome in atherosclerotic cardiovascular disease. Nat Commun 8:845

42 Jin M, Qian Z, Yin J, Xu W, Zhou X (2019) The role of intestinal microbiota in cardiovascular disease. J Cell Mol Med 23:2343–2350

43 Kamo T, Akazawa H, Suda W, Saga-Kamo A, Shimizu Y, Yagi H, Liu Q, Nomura S, Naito AT, Takeda N (2017) Dysbiosis and compositional alterations with aging in the gut microbiota of patients with heart failure. PLoS ONE 12:e0174099

44 Karlsson C, Ahrne S, Molin G, Berggren A, Palmquist I, Fredrikson GN, Jeppsson B (2010) Probiotic therapy to men with incipient arteriosclerosis initiates increased bacterial diversity in colon: a randomized controlled trial. Atherosclerosis 208:228–233

45 Karlsson FH, Fak F, Nookaew I, Tremaroli V, Fagerberg B, Petranovic D, Backhed F, Nielsen J (2012) Symptomatic atherosclerosis is associated with an altered gut metagenome. Nat Commun 3:1245

46 Kasahara K, Krautkramer KA, Org E, Romano KA, Kerby RL, Vivas EI, Mehrabian M, Denu JM, Backhed F, Lusis AJ (2018) Interactions between Roseburia intestinalis and diet modulate atherogenesis in a murine model. Nat Microbiol 3:1461–1471

47 Khalesi S, Sun J, Buys N, Jayasinghe R (2014) Effect of probiotics on blood pressure: a systematic review and meta-analysis of randomized, controlled trials. Hypertension 64:897–903

48 Khalesi S, Bellissimo N, Vandelanotte C, Williams S, Stanley D, Irwin C (2019) A review of probiotic supplementation in healthy adults: helpful or hype? Eur J Clin Nutr 73:24–37

49 Koeth RA, Wang Z, Levison BS, Buffa JA, Org E, Sheehy BT, Britt EB, Fu X, Wu Y, Li L (2013) Intestinal microbiota metabolism of L-carnitine, a nutrient in red meat, promotes atherosclerosis. Nat Med 19:576–585

50 Lam V, Su J, Koprowski S, Hsu A, Tweddell JS, Rafiee P, Gross GJ, Salzman NH, Baker JE (2012) Intestinal microbiota determine severity of myocardial infarction in rats. FASEB J 26:1727–1735

51 Lam V, Su J, Hsu A, Gross GJ, Salzman NH, Baker JE (2016) Intestinal microbial metabolites are linked to severity of myocardial infarction in rats. PLoS ONE 11:e0160840

52 Lam KN, Alexander M, Turnbaugh PJ (2019) Precision medicine goes microscopic: engineering the microbiome to improve drug outcomes. Cell Host Microbe 26:22–34

53 Li M, Shu X, Xu H, Zhang C, Yang L, Zhang L, Ji G (2016) Integrative analysis of metabolome and gut microbiota in diet-induced hyperlipidemic rats treated with berberine compounds. J Transl Med 14:237

54 Li J, Zhao F, Wang Y, Chen J, Tao J, Tian G, Wu S, Liu W, Cui Q, Geng B (2017a) Gut microbiota dysbiosis contributes to the development of hypertension. Microbiome 5:14

55 Li XS, Obeid S, Klingenberg R, Gencer B, Mach F, Raber L, Windecker S, Rodondi N, Nanchen D, Muller O (2017b) Gut microbiota-dependent trimethylamine N-oxide in acute coronary syndromes: a prognostic marker for incident cardiovascular events beyond traditional risk factors. Eur Heart J 38:814–824

56 Libby P, Ridker PM, Maseri A (2002) Inflammation and atherosclerosis. Circulation 105:1135–1143

57 Lopez-Mejias R, Genre F, Garcia-Bermudez M, Ubilla B, Castaneda S, Llorca J, Gonzalez-Juanatey C, Corrales A, Miranda-Filloy JA, Pina T (2014) Lack of association between ABO, PPAP2B, ADAMST7, PIK3CG, and EDNRA and carotid intima-media thickness, carotid plaques, and cardiovascular disease in patients with rheumatoid arthritis. Mediators Inflamm 2014:756279

58 Luedde M, Winkler T, Heinsen FA, Ruhlemann MC, Spehlmann ME, Bajrovic A, Lieb W, Franke A, Ott SJ, Frey N (2017) Heart failure is associated with depletion of core intestinal microbiota. ESC Heart Fail 4:282–290

59 Mamic P, Heidenreich PA, Hedlin H, Tennakoon L, Staudenmayer KL (2016) Hospitalized patients with heart failure and common bacterial infections: a nationwide analysis of concomitant clostridium difficile infection rates and in-hospital mortality. J Card Fail 22:891–900

60 Marques FZ, Nelson E, Chu PY, Horlock D, Fiedler A, Ziemann M, Tan JK, Kuruppu S, Rajapakse NW, El-Osta A (2017) Highfiber diet and acetate supplementation change the gut microbiota and prevent the development of hypertension and heart failure in hypertensive mice. Circulation 135:964–977

61 Maruvada P, Leone V, Kaplan LM, Chang EB (2017) The human microbiome and obesity: moving beyond associations. Cell Host Microbe 22:589–599

62 Mell B, Jala VR, Mathew AV, Byun J, Waghulde H, Zhang Y, Haribabu B, Vijay-Kumar M, Pennathur S, Joe B (2015) Evidence for a link between gut microbiota and hypertension in the Dahl rat. Physiol Genomics 47:187–197

63 Mencarelli A, Cipriani S, Renga B, Bruno A, D’Amore C, Distrutti E, Fiorucci S (2012) VSL#3 resets insulin signaling and protects against NASH and atherosclerosis in a model of genetic dyslipidemia and intestinal inflammation. PLoS ONE 7:e45425

64 Molin G (2001) Probiotics in foods not containing milk or milk constituents, with special reference to Lactobacillus plantarum 299v. Am J Clin Nutr 73:380S–385S

65 Naruszewicz M, Johansson ML, Zapolska-Downar D, Bukowska H (2002) Effect of Lactobacillus plantarum 299v on cardiovascular disease risk factors in smokers. Am J Clin Nutr 76:1249–1255

66 Natarajan N, Hori D, Flavahan S, Steppan J, Flavahan NA, Berkowitz DE, Pluznick JL (2016) Microbial short chain fatty acid metabolites lower blood pressure via endothelial G proteincoupled receptor 41. Physiol Genomics 48:826–834

67 Nemet I, Saha PP, Gupta N, Zhu W, Romano KA, Skye SM, Cajka T, Mohan ML, Li L, Wu Y (2020) A cardiovascular diseaselinked gut microbial metabolite acts via adrenergic receptors. Cell 180(862–877):e822

68 Ott SJ, El Mokhtari NE, Musfeldt M, Hellmig S, Freitag S, Rehman A, Kuhbacher T, Nikolaus S, Namsolleck P, Blaut M (2006) Detection of diverse bacterial signatures in atherosclerotic lesions of patients with coronary heart disease. Circulation 113:929–937

69 Ozdal T, Sela DA, Xiao J, Boyacioglu D, Chen F, Capanoglu E (2016) The reciprocal interactions between polyphenols and gut microbiota and effects on bioaccessibility. Nutrients 8:78

70 Pasini E, Aquilani R, Testa C, Baiardi P, Angioletti S, Boschi F, Verri M, Dioguardi F (2016) Pathogenic gut flora in patients with chronic heart failure. JACC Heart Fail 4:220–227

71 Pluznick J (2014) A novel SCFA receptor, the microbiota, and blood pressure regulation. Gut Microbes 5:202–207

72 Pluznick JL, Protzko RJ, Gevorgyan H, Peterlin Z, Sipos A, Han J, Brunet I, Wan LX, Rey F, Wang T (2013) Olfactory receptor responding to gut microbiota-derived signals plays a role in renin secretion and blood pressure regulation. Proc Natl Acad Sci USA 110:4410–4415

73 Poesen R, Claes K, Evenepoel P, de Loor H, Augustijns P, Kuypers D, Meijers B (2016) Microbiota-derived phenylacetylglutamine associates with overall mortality and cardiovascular disease in patients with CKD. J Am Soc Nephrol 27:3479–3487

74 Portugal LR, Goncalves JL, Fernandes LR, Silva HP, Arantes RM, Nicoli JR, Vieira LQ, Alvarez-Leite JI (2006) Effect of Lactobacillus delbrueckii on cholesterol metabolism in germ-free mice and on atherogenesis in apolipoprotein E knock-out mice. Braz J Med Biol Res 39:629–635

75 Qi Y, Aranda JM, Rodriguez V, Raizada MK, Pepine CJ (2015) Impact of antibiotics on arterial blood pressure in a patient with resistant hypertension—a case report. Int J Cardiol 201:157–158

76 Qin J, Li R, Raes J, Arumugam M, Burgdorf KS, Manichanh C, Nielsen T, Pons N, Levenez F, Yamada T (2010) A human gut microbial gene catalogue established by metagenomic sequencing. Nature 464:59–65

77 Rajendhran J, Shankar M, Dinakaran V, Rathinavel A, Gunasekaran P (2013) Contrasting circulating microbiome in cardiovascular disease patients and healthy individuals. Int J Cardiol 168:5118–5120

78 Roberts AB, Gu X, Buffa JA, Hurd AG, Wang Z, Zhu W, Gupta N, Skye SM, Cody DB, Levison BS (2018) Development of a gut microbe-targeted nonlethal therapeutic to inhibit thrombosis potential. Nat Med 24:1407–1417

79 Ronda C, Chen SP, Cabral V, Yaung SJ, Wang HH (2019) Metagenomic engineering of the mammalian gut microbiome in situ. Nat Methods 16:167–170

80 Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, Schroedl W, Karhausen T, Doehner W, Rauchhaus M (2007) Altered intestinal function in patients with chronic heart failure. J Am Coll Cardiol 50:1561–1569

81 Sandek A, Bjarnason I, Volk HD, Crane R, Meddings JB, Niebauer J, Kalra PR, Buhner S, Herrmann R, Springer J (2012) Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure. Int J Cardiol 157:80–85

82 Santisteban MM, Qi Y, Zubcevic J, Kim S, Yang T, Shenoy V, ColeJeffrey CT, Lobaton GO, Stewart DC, Rubiano A (2017) Hypertension-linked pathophysiological alterations in the gut. Circ Res 120:312–323

83 Sekirov I, Russell SL, Antunes LC, Finlay BB (2010) Gut microbiota in health and disease. Physiol Rev 90:859–904

84 Seldin MM, Meng Y, Qi H, Zhu W, Wang Z, Hazen SL, Lusis AJ, Shih DM (2016) Trimethylamine N-oxide promotes vascular inflammation through signaling of mitogen-activated protein kinase and nuclear factor-kappaB. J Am Heart Assoc 5.

85 Senthong V, Wang Z, Fan Y, Wu Y, Hazen SL, Tang WH (2016a) Trimethylamine N-oxide and mortality risk in patients with peripheral artery disease. J Am Heart Assoc 5.

86 Senthong V, Wang Z, Li XS, Fan Y, Wu Y, Tang WH, Hazen SL (2016b) Intestinal microbiota-generated metabolite trimethylamine-N-oxide and 5-year mortality risk in stable coronary artery disease: the contributory role of intestinal microbiota in a COURAGE-like patient cohort. J Am Heart Assoc 5.

87 Shimizu M, Hashiguchi M, Shiga T, Tamura HO, Mochizuki M (2015) Meta-analysis: effects of probiotic supplementation on lipid profiles in normal to mildly hypercholesterolemic individuals. PLoS ONE 10:e0139795

88 Tang WH, Hazen SL (2017) The gut microbiome and its role in cardiovascular diseases. Circulation 135:1008–1010

89 Tang WH, Wang Z, Levison BS, Koeth RA, Britt EB, Fu X, Wu Y, Hazen SL (2013) Intestinal microbial metabolism of phosphatidylcholine and cardiovascular risk. N Engl J Med 368:1575–1584

90 Tang WH, Wang Z, Fan Y, Levison B, Hazen JE, Donahue LM, Wu Y, Hazen SL (2014) Prognostic value of elevated levels of intestinal microbe-generated metabolite trimethylamine-N-oxide in patients with heart failure: refining the gut hypothesis. J Am Coll Cardiol 64:1908–1914

91 Tang WH, Wang Z, Shrestha K, Borowski AG, Wu Y, Troughton RW, Klein AL, Hazen SL (2015) Intestinal microbiota-dependent phosphatidylcholine metabolites, diastolic dysfunction, and adverse clinical outcomes in chronic systolic heart failure. J Card Fail 21:91–96

92 Trichopoulou A, Bamia C, Trichopoulos D (2009) Anatomy of health effects of Mediterranean diet: Greek EPIC prospective cohort study. BMJ 338:b2337

93 Turnbaugh PJ (2020) Diet should be a tool for researchers, not a treatment. Nature 577:S23

94 Vaghef-Mehrabany E, Vaghef-Mehrabany L, Asghari-Jafarabadi M, Homayouni-Rad A, Issazadeh K, Alipour B (2017) Effects of probiotic supplementation on lipid profile of women with rheumatoid arthritis: A randomized placebo-controlled clinical trial. Health Promot Perspect 7:95–101

95 van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de Vos WM, Visser CE, Kuijper EJ, Bartelsman JF, Tijssen JG (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415

96 Vrieze A, Van Nood E, Holleman F, Salojarvi J, Kootte RS, Bartelsman JF, Dallinga-Thie GM, Ackermans MT, Serlie MJ, Oozeer R (2012) Transfer of intestinal microbiota from lean donors increases insulin sensitivity in individuals with metabolic syndrome. Gastroenterology 143(913–916):e917

97 Walter J, Armet AM, Finlay BB, Shanahan F (2020) Establishing or exaggerating causality for the gut microbiome: lessons from human microbiota-associated rodents. Cell 180:221–232

98 Wang Z, Zhao Y (2018) Gut microbiota derived metabolites in cardiovascular health and disease. Protein Cell 9:416–431

99 Wang Z, Klipfell E, Bennett BJ, Koeth R, Levison BS, Dugar B, Feldstein AE, Britt EB, Fu X, Chung YM (2011) Gut flora metabolism of phosphatidylcholine promotes cardiovascular disease. Nature 472:57–63

100 Wang Z, Tang WH, Buffa JA, Fu X, Britt EB, Koeth RA, Levison BS, Fan Y, Wu Y, Hazen SL (2014) Prognostic value of choline and betaine depends on intestinal microbiota-generated metabolite trimethylamine-N-oxide. Eur Heart J 35:904–910

101 Wang Z, Roberts AB, Buffa JA, Levison BS, Zhu W, Org E, Gu X, Huang Y, Zamanian-Daryoush M, Culley MK (2015) Nonlethal inhibition of gut microbial trimethylamine production for the treatment of atherosclerosis. Cell 163:1585–1595

102 Wang L, Zhu Q, Lu A, Liu X, Zhang L, Xu C, Liu X, Li H, Yang T (2017) Sodium butyrate suppresses angiotensin II-induced hypertension by inhibition of renal (pro)renin receptor and intrarenal renin-angiotensin system. J Hypertens 35:1899–1908

103 Wilck N, Matus MG, Kearney SM, Olesen SW, Forslund K, Bartolomaeus H, Haase S, Mahler A, Balogh A, Marko L (2017) Salt-responsive gut commensal modulates TH17 axis and disease. Nature 551:585–589

104 Wu XM, Tan RX (2019) Interaction between gut microbiota and ethnomedicine constituents. Nat Prod Rep 36:788–809

105 Xiao S, Fei N, Pang X, Shen J, Wang L, Zhang B, Zhang M, Zhang X, Zhang C, Li M (2014) A gut microbiota-targeted dietary intervention for amelioration of chronic inflammation underlying metabolic syndrome. FEMS Microbiol Ecol 87:357–367

106 Xu Z, Knight R (2015) Dietary effects on human gut microbiome diversity. Br J Nutr 113(Suppl):S1–5

107 Xue L, He J, Gao N, Lu X, Li M, Wu X, Liu Z, Jin Y, Liu J, Xu J (2017) Probiotics may delay the progression of nonalcoholic fatty liver disease by restoring the gut microbiota structure and improving intestinal endotoxemia. Sci Rep 7:45176

108 Yan Q, Gu Y, Li X, Yang W, Jia L, Chen C, Han X, Huang Y, Zhao L, Li P (2017) Alterations of the gut microbiome in hypertension. Front Cell Infect Microbiol 7:381

109 Yang T, Santisteban MM, Rodriguez V, Li E, Ahmari N, Carvajal JM, Zadeh M, Gong M, Qi Y, Zubcevic J (2015) Gut dysbiosis is linked to hypertension. Hypertension 65:1331–1340

110 Zhang F, Cui B, He X, Nie Y, Wu K, Fan D, Group FMSS (2018) Microbiota transplantation: concept, methodology and strategy for its modernization. Protein Cell 9:462–473

111 Zhang F, Zhang T, Zhu H, Borody TJ (2019) Evolution of fecal microbiota transplantation in methodology and ethical issues. Curr Opin Pharmacol 49:11–16

112 Zhou X, Li J, Guo J, Geng B, Ji W, Zhao Q, Li J, Liu X, Liu J, Guo Z (2018) Gut-dependent microbial translocation induces inflammation and cardiovascular events after ST-elevation myocardial infarction. Microbiome 6:66

113 Zhu W, Lin K, Li K, Deng X, Li C (2018) Reshaped fecal gut microbiota composition by the intake of high molecular weight persimmon tannin in normal and high-cholesterol diet-fed rats. Food Funct 9:541–551

114 Ziganshina EE, Sharifullina DM, Lozhkin AP, Khayrullin RN, Ignatyev IM, Ziganshin AM (2016) Bacterial communities associated with atherosclerotic plaques from russian individuals with atherosclerosis. PLoS ONE 11:e0164836

115 Zuo K, Li J, Li K, Hu C, Gao Y, Chen M, Hu R, Liu Y, Chi H, Wang H (2019a) Disordered gut microbiota and alterations in metabolic patterns are associated with atrial fibrillation. Gigascience 8.

116 Zuo K, Li J, Wang P, Liu Y, Liu Z, Yin X, Liu X, Yang X (2019b) Duration of persistent atrial fibrillation is associated with alterations in human gut microbiota and metabolic phenotypes. mSystems 4.

117 Zuo K, Li J, Xu Q, Hu C, Gao Y, Chen M, Hu R, Liu Y, Chi H, Yin Q (2019c) Dysbiotic gut microbes may contribute to hypertension by limiting vitamin D production. Clin Cardiol 42:710